Execs Could Go To Jail For False Info In FDA Submissions Under Senate Bill
This article was originally published in The Gray Sheet
Executive Summary
Device and drug company executives could face prison time if a submission to FDA turns out to be false or misleading, under a bill introduced in the Senate July 31
You may also be interested in...
Bill Calls For Institute Of Medicine Review Of Device Approval Process
The Institute of Medicine would have until September 2010 to perform a top-to-bottom assessment of FDA's device pre-market review programs and to recommend reforms under a provision in a bill introduced in the Senate April 23
Bill Calls For Institute Of Medicine Review Of Device Approval Process
The Institute of Medicine would have until September 2010 to perform a top-to-bottom assessment of FDA's device pre-market review programs and to recommend reforms under a provision in a bill introduced in the Senate April 23
Industry Opposes Idea Of New FDA Inspection Authority, Fee At House Hearing
Several device industry representatives told lawmakers on Capitol Hill May 14 that additional FDA user fees and expansion of pre-approval inspection authority to include less risky, Class II devices should not be part of a proposed bill making its way through Congress. They got support from the Republican members of the panel